2025년 플레너리 세션(기조 강연 프로그램)

전 세계의 동료들과 함께 Discovery on Target 플레너리 세션(기조 강연 프로그램)에 참여하세요. 플레너리 기조 프레젠테이션은 이벤트의 전반과 후반을 연결하는 가교가 됩니다. Drug Discovery 전문가의 DOT 커뮤니티 전체가 한자리에 모여 업계 저명인사로부터 전체상, 혁신적인 기술, 생각을 자극하는 동향에 대해 배울 수 있는 유일한 기회입니다. 이날 오후에는 벤처캐피털의 플레너리 패널로부터 Drug Discovery의 최신 동향에 대해 들을 수 있습니다. 이후 생명과학에 영향을 미치는 다양한 주제와 변화를 만들기 위해 함께 대처할 수 있는 방법에 대해 논의하는 콜라보레이션 토론이 진행됩니다.

WEDNESDAY, SEPTEMBER 24

11:05 am The Radicalization of Drug Discovery
Gregory L. Verdine, PhD, President & CEO, LifeMine Therapeutics
The field of drug discovery stands at a watershed moment of scientific, medical, and commercial opportunity. Realization of this opportunity will require radical innovations that fundamentally expand the functional capabilities of therapeutic interventions and management of the attendant risks. This talk will focus on the discovery, development, and deployment of radically new therapeutic modalities, inspired by nature, that thrust the field forward in non-obvious, impactful, and exciting new directions.

Gregory L. Verdine is Erving Professor of Chemistry and Harvard College Professor, emeritus, at Harvard University and Harvard Medical School; Co-founder, President and Chief Executive Officer of LifeMine Therapeutics (with co-founders Rick Klausner and WeiQing Zhou); Co-founder (with Hal Barron) and Executive Chairman of VidaVinci; and Venture Partner at Andreessen Horowitz. Verdine is an award-winning university educator, pioneering life scientist and innovator, new modality drug discovery entrepreneur, venture capitalist and successful zero-to-one biotech company-builder. He is a Fellow of the Royal Society of Chemistry and the American Association for the Advancement of Science; he has received a Presidential Investigator Award, the Nobel Laureate Signature Award, the AARC Award for Excellence in Chemistry in Cancer Research and an honorary PhD degree from Clarkson University and MS degree from Harvard University. Verdine received Bachelor of Science and doctoral degrees in chemistry from St. Joseph’s University and Columbia University, respectively.

11:40 am GLP-1 Unveiled: Key Takeaways for Next-Generation Drug Discovery
Lotte Bjerre Knudsen, PhD, Chief Scientific Advisor, Head of IDEA (Innovation & Data Experimentation Advancement), Novo Nordisk AS
This talk will explore the evolution of GLP-1 as a significant component in diabetes and obesity treatment, as well as its direct impact on multiple co-morbidities. It will highlight the role of industry innovation and scientific persistence in overcoming challenges posed by its short half-life, ultimately leading to the successful development of GLP-1 therapies. Key lessons from this journey will inform future drug discovery strategies, emphasizing that today's drug discovery must be based on human data.

Lotte Bjerre Knudsen is a Danish national, born in 1964 in a small town near Copenhagen. She holds a degree in biotechnology from the Technical University of Denmark, and a Doctoral degree in Scientific Medicine from the University of Copenhagen, Denmark. Lotte has been with Novo Nordisk since her university graduation in 1989 and has since then held several positions within the company and is today Chief Scientific Advisor in Research & Early Development and heads up IDEA (Innovation and Data Experimentation Advancement). She has deep experience across the entire value chain of drug discovery and development and has published extensively. Lotte is an inventor on many patents, all fully owned by Novo Nordisk. She has been part of representing Novo Nordisk in five FDA Advisory committees. Lotte has received numerous awards. Most recently, she was the recipient the Paul Langerhans Award from the German Diabetes Association and a co-recipient of the American Association for the Advancement of Science Mani Bhaumik Breakthrough of the Year Award, the Lasker Foundation Lasker-DeBakey Clinical Award and the Breakthrough Prize in Life Sciences.

VENTURE CAPITALIST INSIGHTS

4:15 pm PANEL DISCUSSION: Venture Capitalist Insights into Trends in Drug Discovery
PANEL MODERATOR: Daniel A. Erlanson, PhD, Chief Innovation Officer, Frontier Medicines Corporation

PANELISTS:
Olga Danilchanka, PhD, Principal, MRL Ventures Fund

Jamie Kasuboski, PhD, Partner, Luma Group

Chris De Savi, PhD, CSO Partner, Curie Bio

Devin Quinlan, PhD, Principal, Investment, MPM BioImpact Inc.

Brendan Kelly, PhD, Principal, Lightstone Ventures

Blair Willette, PhD, Associate, KdT Ventures

Topics to be discussed:

• Key drivers of innovation in drug discovery
• Overcoming hurdles in translating discoveries from the lab to the clinic
• Impact of AI/machine learning, emerging drug modalities, pursuit of challenging drug targets
• Navigating the current regulatory and funding environment
• Perspectives on upcoming challenges and opportunities in drug development

COLLABORATIVE CONVERSATION

5:15 pm Connecting the DOTs to Spark Change!
Join us for an hour of inspiring, informal discussions on how to forge connections and create impactful ecosystems that will help you think, act, and thrive. We have invited pharma, biotech, and academic leaders to share their stories and experiences and to discuss key learnings. There will be time for open discussion and networking. This session will not be recorded for on-demand viewing.

Topics for discussion will include, but certainly not be limited to: